Group 1 - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as one of the best medical stocks to buy currently, with a Hold rating maintained by RBC Capital analyst Brian Abrahams and a price target set at $98.00 [1] - For fiscal Q2 2025, Gilead reported a 2% growth in total revenues, reaching $7.1 billion, attributed to increased sales of HIV treatments, Livdelzi, and Trodelvy [2] - The diluted EPS for the quarter was $1.56, an increase from $1.29 in the prior year, driven by net unrealized gains on securities and higher product sales [3] Group 2 - Gilead's portfolio includes drugs targeting serious diseases such as cancer, HIV, viral hepatitis, and COVID-19, focusing on medical areas with unmet needs [4] - The company operates in over 35 countries, indicating a broad international presence [4]

Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a strong large-cap value stock with a maintained Buy rating and a price target of $143.00 by Morgan Stanley analyst Terence Flynn [1] - The positive outlook for Gilead is supported by a recent recommendation from the US CDC for its product Yeztugo for HIV pre-exposure prophylaxis (PrEP) [2] - JPMorgan analyst Chris Schott has increased the price target for Gilead from $135 to $145 while maintaining an Overweight rating, indicating confidence in the company's growth potential [3] Company Overview - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19 [3] - The company's drug portfolio addresses medical areas with unmet needs and includes products such as AmBisome, Atripla, Biktarvy, Cayston, and Complera [4] - Gilead operates in over 35 countries, highlighting its global presence and market reach [4]

Group 1 - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as one of the best drug stocks to buy currently, with a Buy rating maintained by Simon Baker CFA from Redburn Atlantic and a price target set at $143.00 [1] - The company received marketing authorization for Yeytuo (lenacapavir) from the European Commission, marking it as the first and only twice-yearly injectable HIV-1 capsid inhibitor approved for pre-exposure prophylaxis (PrEP) in the EU member states [2] - Gilead Sciences operates in over 35 countries and focuses on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that includes drugs like AmBisome, Atripla, and Biktarvy [2]

Core Viewpoint - Analysts expect Gilead Sciences to report quarterly earnings of $1.73 per share, reflecting a year-over-year increase of 231.1%, with revenues projected at $6.83 billion, up 2.2% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.9% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [1][2]. Revenue and Product Sales Projections - Total product sales are expected to reach $6.75 billion, indicating a year-over-year change of +1.6% [4]. - Royalty contract and other revenues are estimated at $40.04 million, reflecting a +2.7% change from the prior year [4]. - Product Sales for HIV (Genvoya) are projected at $375.96 million, showing a decline of -6.7% year over year [4]. - Product Sales for HIV (Odefsey) are expected to be $294.72 million, down -4.9% from the previous year [5]. - Oncology product sales (Tecartus) are forecasted at $56.12 million, indicating a +2% change [5]. - Liver Disease product sales (Sofosbuvir/Velpatasvir) are estimated at $238.12 million, down -4% from the year-ago quarter [6]. - Other product sales (Other) are projected at $40.07 million, reflecting a significant decline of -32.1% [6]. - Total HIV product sales in the U.S. are expected to reach $3.56 billion, indicating a +4.6% change year over year [7]. Additional Product Sales Insights - Product Sales for HIV (Genvoya) in the U.S. are projected at $299.29 million, down -9.9% from the previous year [7]. - Liver Disease product sales (Vemlidy) are expected to be $96.60 million, reflecting a +1.7% change [8]. - Other product sales (AmBisome) are projected at $11.31 million, down -19.2% from the prior year [8]. - Product Sales for Veklury are expected to be $277.30 million, indicating a -12% change year over year [8]. Stock Performance - Gilead shares have experienced a -1.3% change over the past month, compared to a -6.9% move in the Zacks S&P 500 composite [9].